Cvetković Zorica, Marković Olivera, Marinković Gligorije, Pejić Snežana, Vučić Vesna
Department of Hematology, University Hospital Medical Center Zemun, 11080 Belgrade, Serbia.
Faculty of Medicine, University of Belgrade, 11000 Belgrade, Serbia.
Int J Mol Sci. 2025 Jun 13;26(12):5670. doi: 10.3390/ijms26125670.
Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma, characterized by significant variability in clinical outcomes. Emerging evidence highlights the pivotal role of inflammation in the pathogenesis and prognosis of DLBCL. This narrative review explores the interplay between the tumor microenvironment, inflammatory processes, and prognostic indices used in DLBCL, focusing on biomarkers, immune responses, and systemic inflammation. These indices show promise as predictive and prognostic tools comparable to molecular markers, such as gene expression profiling, which are currently considered gold standards in prognosis but are often costly and technically demanding. By synthesizing findings from the current literature, this article highlights the potential of inflammatory indices as accessible and cost-effective prognostic alternatives to molecular markers in DLBCL, while also underscoring the need for further research to validate their clinical utility.
弥漫性大B细胞淋巴瘤（DLBCL）是非霍奇金淋巴瘤最常见的亚型，其临床结局存在显著差异。新出现的证据凸显了炎症在DLBCL发病机制和预后中的关键作用。这篇叙述性综述探讨了肿瘤微环境、炎症过程以及DLBCL中使用的预后指标之间的相互作用，重点关注生物标志物、免疫反应和全身炎症。这些指标有望成为与分子标志物相当的预测和预后工具，如基因表达谱分析，目前基因表达谱分析被视为预后的金标准，但往往成本高昂且技术要求高。通过综合当前文献的研究结果，本文强调了炎症指标作为DLBCL中分子标志物的可及且经济有效的预后替代指标的潜力，同时也强调了进一步研究以验证其临床效用的必要性。
